|
| Status |
Public on Mar 07, 2021 |
| Title |
RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761 |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We employed the patient-derived xenografts (PDX) model to test the efficiency of LY2109761 in vivo. The drug was intraperitoneally administered, and the mice were sacrificed on the 31st day. The tumors were excised and subjected to RNA-seq. All groups had similar expression density distributions. Hierarchical clustering showed that the same processing groups had the closest distances.
|
| |
|
| Overall design |
Examination of differential expressive genes in glioma tissues from PDX treated by DMSO or LY2109761.
|
| |
|
| Contributor(s) |
Wang Q, Cai J, Zhang J, Kang C |
| Citation(s) |
30279734 |
| Submission date |
Mar 12, 2018 |
| Last update date |
Jun 07, 2021 |
| Contact name |
Jinquan Cai |
| E-mail(s) |
caijinquan666777@126.com
|
| Organization name |
Harbin Medical University
|
| Street address |
Xuefu Road
|
| City |
Harbin |
| ZIP/Postal code |
150086 |
| Country |
China |
| |
|
| Platforms (1) |
|
| Samples (8)
|
|
| This SubSeries is part of SuperSeries: |
| GSE111676 |
Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-Beta pathway |
|
| Relations |
| BioProject |
PRJNA437856 |
| SRA |
SRP134909 |
Less...
More...